As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
Similar Posts
Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
Medical devices: conformity assessment and the UKCA mark
How to conform with the legal requirements for placing medical devices on the market.
Guidance: Health Institution Exemption for general medical devices
Guidance for health institutions that manufacture general medical devices under the Health Institution Exemption (HIE).
Guidance: Borderline products: medical devices and other products
How the MHRA makes decisions on whether a borderline product is a medical device and whether medical devices regulations should apply.
Medicines: apply for a parallel import licence
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.
Field Safety Notices: 28 July to 1 August 2025
List of Field Safety Notices from 28 July to 1 August 2025.